Medication Comparison · Updated March 2026

Ozempic vs Wegovy: Same Drug, Different Doses and Labels

Ozempic and Wegovy are both semaglutide, made by the same company (Novo Nordisk). But they are not identical. Wegovy goes to a higher dose, has a weight management indication, carries cardiovascular outcome data, and is now available as an oral pill. This comparison covers every practical difference that matters when you are choosing between them.

TL;DR

• Both are semaglutide by Novo Nordisk. Same active ingredient, same mechanism of action.
• Wegovy maxes out at 2.4 mg/week. Ozempic maxes out at 2 mg/week. That higher dose matters for weight loss.
• Ozempic is FDA-approved for type 2 diabetes (2017). Wegovy is FDA-approved for weight management (2021). Many people use Ozempic off-label for weight loss.
• Ozempic is ~$892/mo. Wegovy is ~$1,349/mo at brand list price. Ozempic is often easier and cheaper to get through insurance.
• Wegovy now has a pill form (FDA-approved 2025). Ozempic is injection-only.
• Wegovy has SELECT cardiovascular data showing a 20% reduction in major cardiac events.

Quick Comparison Table

Active Ingredient: The Same Molecule

Ozempic and Wegovy both contain semaglutide, a GLP-1 receptor agonist. It works by mimicking the GLP-1 hormone your gut naturally produces after eating. Semaglutide slows gastric emptying (so food stays in your stomach longer), reduces appetite signals in the brain, and improves how your body handles insulin.

The molecule is identical in both drugs. Novo Nordisk manufactures both. Where they differ: the maximum dose, the FDA label, and (now) the available formulations.

The Dose Difference: Why It Matters

This is the most important clinical distinction between Ozempic and Wegovy.

Ozempic doses (weekly injection):

• 0.25 mg (starting, 4 weeks)
• 0.5 mg
• 1 mg
• 2 mg (max)

Wegovy doses (weekly injection):

• 0.25 mg (starting, 4 weeks)
• 0.5 mg
• 1 mg
• 1.7 mg
• 2.4 mg (max)

Wegovy’s max dose is 20% higher than Ozempic’s. In the weight loss trials, that extra 0.4 mg translated into meaningful additional weight loss. The STEP 1 trial at 2.4 mg showed 14.9% body weight loss. Ozempic at 2 mg produces roughly 15% as well (from STEP 8, which compared semaglutide to tirzepatide), but the 2.4 mg dose in Wegovy is specifically optimized for the weight management population.

In practice, the difference between 2 mg and 2.4 mg may not be dramatic for every individual. But for people who are not seeing enough results at 2 mg, having the option to go to 2.4 mg matters.

Wegovy oral pill (approved 2025):

• Taken daily (not weekly)
• Doses up to 25 mg/day
• The pill version gives comparable weight loss to the injection in clinical trials

The oral pill is a significant new option. See our full Wegovy pill vs injection comparison for details.

FDA Status and Off-Label Use

Ozempic has been FDA-approved for type 2 diabetes since 2017. It is one of the most prescribed diabetes medications in the US. Millions of people take it.

Wegovy was FDA-approved for chronic weight management in 2021 for adults with a BMI of 30 or higher (or 27+ with a weight-related condition).

Here is the reality that most articles dance around: a large number of people take Ozempic off-label specifically for weight loss. Their doctors prescribe Ozempic instead of Wegovy because it is cheaper, better covered by insurance, and contains the same molecule. This is legal. Doctors can prescribe FDA-approved medications for off-label uses based on their clinical judgment.

The off-label route has trade-offs, though. Ozempic’s max dose is lower (2 mg vs 2.4 mg). It does not have weight management clinical data supporting its use for that purpose specifically. And insurance companies can (and sometimes do) deny coverage if the diagnosis code does not match the indication.

Weight Loss Data

Both drugs produce substantial weight loss. The data:

Wegovy (STEP 1 trial, 2.4 mg, 68 weeks):

• Average weight loss: 14.9%
• About one-third of participants lost 20%+ of body weight
• Placebo group: 2.4%

Ozempic (STEP 8 trial, 2 mg, 68 weeks):

• Average weight loss: ~15% (similar to Wegovy)
• This trial compared semaglutide to tirzepatide

Head-to-head with tirzepatide (SURMOUNT-5, 72 weeks):

• Semaglutide (2.4 mg): 13.7% weight loss
• Tirzepatide (up to 15 mg): 20.2% weight loss

If you are comparing semaglutide to tirzepatide, tirzepatide wins on weight loss. But within the semaglutide family, Ozempic and Wegovy produce very similar results. The 2 mg vs 2.4 mg dose gap is real but not enormous for most people.

For a full comparison across all GLP-1 medications, see our Mounjaro vs Ozempic vs Wegovy vs Zepbound page.

Cardiovascular Data: Wegovy’s Major Advantage

The SELECT trial is Wegovy’s strongest differentiator from Ozempic. This trial enrolled over 17,600 adults with obesity and established cardiovascular disease. Participants received semaglutide 2.4 mg (the Wegovy dose) or placebo.

Results over a median of 40 months: a 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death).

This is not a weight loss finding. It is a cardiovascular outcome finding. The FDA updated Wegovy’s label to include a cardiovascular risk reduction indication based on SELECT.

Ozempic does not have equivalent cardiovascular outcome data for the weight management population. The SUSTAIN 6 trial showed cardiovascular benefits for Ozempic in diabetes patients, but that was at lower doses and in a different population.

If you have existing heart disease or significant cardiovascular risk factors, the SELECT data gives Wegovy a clear edge. Discuss this with your prescriber.

Side Effects

Same molecule, same side effects. The GI issues are the main concern:

• Nausea: Most common. Usually peaks in the first week or two at each new dose.
• Diarrhea and constipation: Opposite ends of the same spectrum. Some people get one, some get the other.
• Vomiting: Less common but possible, especially at higher doses.
• Decreased appetite: Expected. This is the drug working.
• Fatigue and headache: Reported in early weeks.

Rates from STEP trials (2.4 mg semaglutide):

• Nausea: 43.9%
• Diarrhea: 29.7%
• Vomiting: 24.5%
• Constipation: 24.2%

These numbers look high, but 99.5% of GI events were classified as non-serious. Most people tolerate the drug well after the initial adjustment. Discontinuation due to side effects was roughly 7% in the STEP trials.

Wegovy’s higher max dose (2.4 mg vs 2 mg) may cause slightly more GI issues at the top end, but the escalation schedule helps minimize this. Full breakdown in our GLP-1 side effects guide.

Cost Comparison

Ozempic is $457 cheaper per month at list price. For many people without insurance coverage for either drug, that price gap is significant.

The more common scenario: your insurance covers Ozempic for diabetes but does not cover Wegovy for weight loss. In that case, Ozempic at $25-$100/mo with insurance versus Wegovy at $1,349/mo out of pocket is not a close decision. This is exactly why so many people use Ozempic off-label for weight loss.

For a complete pricing comparison, see our cheapest GLP-1 online guide.

Insurance Coverage

Ozempic Coverage

Ozempic has been on the market since 2017 for type 2 diabetes. It is on nearly every major commercial insurance formulary for diabetes. Prior authorization may be required, but approval rates are high when the diagnosis is T2D.

For weight loss (off-label): Coverage varies. Some plans will cover Ozempic for a BMI-related diagnosis even without diabetes. Many will not. If you do not have diabetes, getting Ozempic covered is less predictable.

Wegovy Coverage

Wegovy was approved for weight management in 2021. Coverage has been expanding, particularly after the SELECT cardiovascular data was published. More commercial plans and some state Medicaid programs now include Wegovy.

The challenge: Many employer-sponsored plans still exclude anti-obesity medications. Medicare Part D does not cover weight loss drugs. The SELECT data has pushed some insurers to add Wegovy, but it is still far from universal.

The Off-Label Calculation

Here is the reality most people face: if you have type 2 diabetes, Ozempic is the easier insurance path. If you are using semaglutide for weight loss only, Wegovy is on-label but may not be covered. Many prescribers will try Ozempic first because insurance coverage is more reliable, then switch to Wegovy if the patient needs the higher 2.4 mg dose or if the insurer requires on-label prescribing.

See our GLP-1 insurance coverage guide for tips on getting approved.

Choose Ozempic If…

• You have type 2 diabetes. Ozempic is on-label for T2D and is broadly covered by insurance.
• Cost is a primary concern. Ozempic is $457/mo cheaper at list price. With insurance, the gap is often even larger.
• Your insurance covers Ozempic but not Wegovy. A covered Ozempic prescription beats an uncovered Wegovy prescription every time.
• You are comfortable at 2 mg max. If the 2 mg dose produces sufficient weight loss for you, the additional 0.4 mg in Wegovy may not be needed.

Choose Wegovy If…

• You want the on-label weight loss indication. If your prescriber prefers on-label prescribing, Wegovy is the FDA-approved option for weight management.
• You have cardiovascular risk factors. The SELECT trial data (20% MACE reduction) gives Wegovy a meaningful clinical advantage for people with existing heart disease.
• You want the oral pill option. The Wegovy pill removes the injection requirement. See our pill vs injection comparison.
• You need the higher 2.4 mg dose. If you have plateaued at 2 mg on Ozempic, Wegovy lets you go to 2.4 mg.
• Your insurance covers Wegovy. If coverage is not an issue, Wegovy is the more complete package: higher dose ceiling, CV data, and the pill option.

What About Compounded Semaglutide?

If neither Ozempic nor Wegovy is affordable, compounded semaglutide is a third route. Compounding pharmacies produce semaglutide at $149-$299/month through telehealth providers.

Compounded versions contain the same active ingredient but are not manufactured by Novo Nordisk. They are produced under the FDA’s shortage policy by 503A and 503B pharmacies. The quality, consistency, and regulatory status of compounded products differ from brand-name. We cover this in detail in our compounded vs brand-name GLP-1 guide.

For many people without insurance, compounded semaglutide is the only affordable option. If you go this route, choose a provider that uses a 503B outsourcing facility (FDA-inspected, cGMP manufacturing standards).

Frequently Asked Questions

Can I switch from Ozempic to Wegovy?

Yes. Since both are semaglutide, switching is straightforward. Your prescriber will typically transition you at the same dose you are already on (for example, from Ozempic 2 mg to Wegovy 2.4 mg). No washout period or restart from the beginning is needed. The main reason to switch is to access the higher 2.4 mg dose or to get on-label coverage for weight management.

Why do so many people use Ozempic for weight loss instead of Wegovy?

Three reasons: (1) Ozempic is cheaper ($892/mo vs $1,349/mo at list price). (2) Ozempic has broader insurance coverage because it is classified as a diabetes drug. (3) The weight loss results at 2 mg are very similar to Wegovy at 2.4 mg for many people. Until Wegovy became more widely covered and the pill option launched, Ozempic off-label was the more practical choice.

Is the Wegovy pill as effective as the injection?

Clinical data shows comparable weight loss between the oral and injectable formulations at their respective maximum doses. The pill is taken daily rather than weekly and requires specific timing (take on an empty stomach, 30 minutes before food or other medications). See our full Wegovy pill vs injection guide.

Does Medicare cover Ozempic or Wegovy?

Medicare Part D covers Ozempic for type 2 diabetes. It does not cover Wegovy or any other medication specifically for weight loss. There is ongoing legislative effort to change this. See our GLP-1 Medicare coverage guide for details.

Are there generics of Ozempic or Wegovy?

No. There are no FDA-approved generic versions of semaglutide as of early 2026. Compounded semaglutide is not a generic. It is a pharmacy-compounded version of the active ingredient, produced under shortage rules, and it has not gone through the FDA approval process as a finished product.

Last updated: March 2026. Pricing and availability may change. This article is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting any medication.